Orforglipron
Orforglipron is an oral small-molecule GLP-1 receptor agonist that, unlike peptide GLP-1 drugs, can be taken as a daily tablet without strict food and water restrictions. Published Phase 2 trials in obesity and type 2 diabetes showed reductions in body weight and HbA1c, and the Phase 3 program (ATTAIN in obesity and ACHIEVE in type 2 diabetes) reported positive results. On the basis of the ATTAIN obesity program, the US FDA approved orforglipron (Foundayo) in April 2026 for chronic weight management. It is not yet approved for type 2 diabetes and is not yet authorized by the EMA or Australia's TGA.
Compare
Mechanism
In plain terms, orforglipron is a pill that mimics the gut hormone GLP-1, which lowers blood sugar and reduces appetite. Technically, it is a non-peptide small molecule that agonizes the GLP-1 receptor; because it is not a peptide it is orally bioavailable and does not require the injection or the fasting administration constraints of oral peptide GLP-1 drugs. Receptor activation stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces food intake.
Regulatory Status by Region
- United States (FDA)Approved. The FDA approved orforglipron (Foundayo) on April 1, 2026 for chronic weight management in adults with obesity, or overweight with weight-related conditions, based on the ATTAIN Phase 3 program. A type 2 diabetes indication (ACHIEVE program) is not yet approved.
- Australia (TGA)Not entered on the Australian Register of Therapeutic Goods (ARTG); not yet approved for supply.
- European Union (EMA)Not authorized; no marketing authorization at this time.
- WADANot listed on the WADA Prohibited List. As a GLP-1 receptor agonist it is not a banned substance.
Key Studies
Related Clinical Trials
- A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health ProblemsPhase 3 · Not Yet Recruiting
- Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy DiscontinuationPhase 4 · Not Yet Recruiting
- PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic ResponsesPhase 4 · Not Yet Recruiting
- IBI3042 Study in Healthy Participants and Overweight or Obese ParticipantsPhase 1 · Recruiting
- A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 DiabetesPhase 3 · Not Yet Recruiting
- A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 ObesityPhase 3 · Recruiting
- A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan FastingPhase 3 · Recruiting
- A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial NeoplasiaPhase 2 · Recruiting
Related News & Research
- ACHIEVE-4 Phase 3 Trial Finds Oral Orforglipron Non-Inferior to Insulin Glargine on Cardiovascular Safety, Published in The Lancet
- This Week in Peptide Research: Orforglipron Dosing Data, GLP-1 Safety Signals, and a Teriparatide-Osteosarcoma Reporting Signal
- ACHIEVE-3: Oral Orforglipron Beat Oral Semaglutide on Blood Sugar and Weight in Head-to-Head Phase 3 Diabetes Trial
- This Week in Peptide Research: GLP-1 Mechanism Studies, LL-37 Engineering Advances, and Kisspeptin's Reach Beyond Reproduction
- Lilly Posts Full Phase 3 Results for Oral Orforglipron in ATTAIN-2 Obesity and Type 2 Diabetes Trial
Latest research
- Safety and tolerability of orforglipron in Japanese people with type 2 diabetes. (opens in a new tab)
The lancet. Diabetes & endocrinology · Oct 1, 2026
- Long-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J): a multicentre, randomised, open-label, parallel-group phase 3 trial. (opens in a new tab)
The lancet. Diabetes & endocrinology · Oct 1, 2026
Common Questions
- What is Orforglipron?
- Orforglipron is a once-daily oral, non-peptide (small-molecule) GLP-1 receptor agonist from Eli Lilly. The US FDA approved it (brand name Foundayo) in April 2026 for chronic weight management in adults with obesity, or overweight with weight-related conditions. It is not yet approved for type 2 diabetes and is not yet authorized by the EMA or Australia's TGA. It is a prescription medicine used under medical supervision.
- Is Orforglipron approved for medical use?
- Orforglipron is approved for one or more medical uses in at least one major jurisdiction. United States (FDA): Approved. The FDA approved orforglipron (Foundayo) on April 1, 2026 for chronic weight management in adults with obesity, or overweight with weight-related conditions, based on the ATTAIN Phase 3 program. A type 2 diabetes indication (ACHIEVE program) is not yet approved. European Union (EMA): Not authorized; no marketing authorization at this time. Australia (TGA): Not entered on the Australian Register of Therapeutic Goods (ARTG); not yet approved for supply.
- How does Orforglipron work?
- In plain terms, orforglipron is a pill that mimics the gut hormone GLP-1, which lowers blood sugar and reduces appetite. Technically, it is a non-peptide small molecule that agonizes the GLP-1 receptor; because it is not a peptide it is orally bioavailable and does not require the injection or the fasting administration constraints of oral peptide GLP-1 drugs.
- Is Orforglipron legal in Australia?
- Orforglipron in Australia (TGA): Not entered on the Australian Register of Therapeutic Goods (ARTG); not yet approved for supply.
- Is Orforglipron banned in sport?
- Orforglipron under the World Anti-Doping Agency (WADA) code: Not listed on the WADA Prohibited List. As a GLP-1 receptor agonist it is not a banned substance.